Cancer Immunotherapy: the LMCT experience

Kris Thielemans

Karine Breckpot

09.11.2017-ORC – slide 1

The Research Program

09.11.2017-ORC – slide 2

The team and its context

09.11.2017-ORC – slide 3

The team and its context

09.11.2017-ORC – slide 4

The team and its context

09.11.2017-ORC – slide 5

The LMCT team

Gender Female to male ratio ±2

Nationalities: 10 Countries: Belgium, China,

Cuba, Germany, Italy,Mexico, Nigeria, Poland,Spain, the Netherlands

09.11.2017-ORC – slide 6

The LMCT output: last 5 years

10

LMCT-members

GRADUATEDin the last 5 years

continued as

POST-

DOCTORAL

FELLOW1PROFESSIONAL PRESENTATIONS

> 150 (inter)national seminars,

conferences and symposia

> 20 news featureson topics such as treatment of melanoma, dendritic

cell vaccines, mRNA vaccines, lentiviral vectors and

nanobodies for tumor targeting

88 SCIENTIFIC PAPERS

09.11.2017-ORC – slide 7

The LMCT output

> 15 patents

5 clinical studies for the treatment

of melanoma, myeloma and hepato-

cellular carcinoma patients

The spin-off eTheRNA Immuno-

therapies NV was founded in 2013

(http://www.etherna.be)

09.11.2017-ORC – slide 8

09.11.2017-ORC – slide 9